Cleared Traditional

K822810 - PHADEBACT CSF TEST 20

K822810 is an FDA 510(k) clearance for PHADEBACT CSF TEST 20, manufactured by Pharmacia, Inc.. The device is a Class 2 Immunology device with product code GTJ cleared through the Traditional 510(k) pathway after a 101-day FDA review.

K822810 · Pharmacia, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1982
Decision
101d
Days
Class 2
Risk

K822810 is an FDA 510(k) clearance for the PHADEBACT CSF TEST 20. Classified as Antisera, All Groups, N. Meningitidis (product code GTJ), Class II - Special Controls.

Submitted by Pharmacia, Inc. (Walker, US). The FDA issued a Cleared decision on December 30, 1982 after a review of 101 days - within the typical 510(k) review window.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.3390 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all Pharmacia, Inc. devices

FDA 510(k) Submission Details - K822810

510(k) Number K822810 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 20, 1982
Decision Date December 30, 1982
Days to Decision 101 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
4d faster than avg
Panel avg: 105d · This submission: 101d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GTJ Device Classification - Class 2, Special Controls

Product Code GTJ Antisera, All Groups, N. Meningitidis
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3390
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.